Author:
Meuth Sven G.,Furmann Moritz J.
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. García-Merino A. Bruton's Tyrosine Kinase Inhibitors: a aew generation of promising agents for multiple sclerosis therapy. Cells. 2021; doi:10.3390/cells10102560
2. Jayagopol LA, Zabad RK. Bruton Tyrosine Kinase Inhibition in Multiple Sclerosis. The missing link for treatment optimization? Pract Neurol. 2022;22(2):29-32
3. Reich DS et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurology. 2021;20(9):729-38
4. Cohen S, Tuckwell K, Katsumoto TR et al. (2020). Fenebrutinib versus placebo or Adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial. Arthritis Rheumatol. 2020;72:1435-46
5. ACTRIMS 2019. - Late Breaking News Posters. Mult Scler. 2019;25:157-65